Diffuse large B-cell lymphoma with central nervous system relapse: Prognosis and risk factors according to retrospective analysis from a single-center experience

International Journal of Hematology

Volumn 89, Issue 5, 2009, Pages 577-583

  Shimazu, Yutaka ^a,b   Notohara, Kenji ^a   Ueda, Yasunori ^a  

^a KURASHIKI CENTRAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

CNS relapse; Diffuse large B cell lymphoma; Retrospective study; Risk factors; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM LYMPHOMA; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PROGNOSIS; RISK FACTOR; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CENTRAL NERVOUS SYSTEM NEOPLASMS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PROGNOSIS; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 67749090800     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12185-009-0289-2     Document Type: Article

References (29)

1. B Coiffier E Lepage J Briere R Herbrecht H Tilly R Bouabdallah 2002 CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma New Eng J Med 346 235 242
2. M Pfreundschuh L Trümper A Osterborg R Pettengell M Trneny K Imrie MabThera International Trial Group 2006 CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group Lancet Oncol 7 379 391
3. LH Sehn J Donaldson M Chhanabhai C Fitzgerald K Gill R Klasa N MacPherson 2005 Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia J Clin Oncol 23 5027 5033
4. K van Besien CS Ha S Murphy P McLaughlin A Rodriguez K Amin 1998 Risk factors, treatment, and outcome of central nervous system recurrence in adults with intermediate-grade and immunoblastic lymphoma Blood 91 1178 1184
5. A Hollender S Kvaloy K Lote O Nome H Holte 2000 Prognostic factors in 140 adult patients with non-Hodgkin's lymphoma with systemic central nervous system (CNS) involvement: a single centre analysis Eur J Cancer 36 1762 1768
6. F Bokstein A Lossos IS Lossos T Siegal 2002 Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy Leuk Lymphoma 43 587 593
7. ND Doolittle LE Abrey TN Shenkier S Tali JE Bromberg EA Neuwelt 2008 Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report Blood 111 1085 1093
8. QA Hill RG Owen 2006 CNS prophylaxis in lymphoma: who to target and what therapy to use Blood Rev 20 319 332
9. N Tomita F Kodama H Kanamori S Motomura Y Ishigatsubo 2006 Secondary central nervous system lymphoma Int J Hematol 84 128 135
10. P Feugier JM Virion H Tilly C Haioun G Marit M Macro 2004 Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab Ann Oncol 15 129 133
11. SL Chua JF Seymour J Streater MM Wolf EH Januszewicz HM Prince 2002 Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma Leuk Lymphoma 43 1783 1788
12. N Tomita F Kodama H Kanamori S Motomura Y Ishigatsubo 2002 Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma Cancer 95 576 580
13. HT Arkenau G Chong D Cunningham D Watkins R Agarwal B Sirohi 2007 The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma Ann Oncol 18 541 545
14. C Haioun C Besson E Lepage C Thieblemont D Simon C Rose 2000 Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients (Groupe d'Etudes des Lymphomes de l'Adulte) Ann Oncol 11 685 690
15. IV Boehme S Zeynalova M Kloess M Loeffler U Kaiser M Pfreundschuh 2007 Incidence and risk factors of central nervous system recurrence in aggressive lymphoma: a survey of 1, 693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL) Ann Oncol 18 149 157
16. A Hollender S Kvaloy O Nome E Skovlund K Lote H Holte 2002 Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model Ann Oncol 13 1099 1107
17. N Keldsen W Michalski SM Bentzen KB Hansen K Thorling 1996 Risk factors for central nervous system involvement in non-Hodgkins-lymphoma: a multivariate analysis Acta Oncologica 35 703 708
18. H Tsurumi T Hara N Goto N Kanemura S Kasahara M Sawada 2007 A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma Hematol Oncol 25 107 114
19. CW Cheung C Burton P Smith DC Linch PJ Hoskin KM Ardeshna 2005 Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK Br J Haematol 131 193 200
20. M Okamoto F Maruyama M Tsuzuki T Nomura H Miyazaki M Wakita 1994 Salvage chemotherapy for relapsed/refractory aggressive non-Hodgkin's lymphoma with a combination of dexamethasone, etoposide, ifosfamide and carboplatin Rinsho Ketsueki 35 635 641
21. S Takasu T Wakabayashi Y Kajita N Hatano H Hatano T Usui 2000 Effectiveness of DeVIC chemotherapy for recurrent primary central nervous system lymphoma No Shinkei Geka 28 789 794
22. L Simpson SM Ansell JP Colgan TM Habermann DJ Inwards KM Ristow 2007 Effectiveness of second-line salvage chemotherapy with ifosfamide, carboplatin, and etoposide in patients with relapsed diffuse large B-cell lymphoma not responding to cis-platinum, cytosine arabinoside, and dexamethasone Leuk Lymphoma 48 1332 1337
23. M Gutierrez BA Chabner D Pearson SM Steinberg ES Jaffe BD Cheson A Fojo WH Wilson 2000 Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH J Clin Oncol 18 3633 3642
24. T Philip C Guglielmi A Hagenbeek R Somers H Van der Lelie D Bron 1995 High-dose therapy and autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma New Engl J Med 333 1540 1545
25. DY Lin 1997 Non-parametric inference for cumulative incidence functions in competing risks studies Stat Med 16 901 910
26. EI Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 55 457
27. Collet D. Modelling survival data in medical research. Boca Raton: Chapman & Hall/CRC; 1999. p. 80-1.
28. T Batchelor JS Loeffler 2006 Primary CNS lymphoma J Clin Oncol 24 1281 1288
29. A Kikuchi H Kawada Y Iwaki S Machida T Tsuchiya R Fukuda 2004 Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma Rinsho Ketsueki 45 1255 1257